# Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

> **NCT03254004** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 70 (estimated)

## Conditions studied

- Lung Adenocarcinoma, Stage I

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03254004
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-08
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254004, "Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03254004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*